Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Curative of Double Hit Diffuse Large B-Cell Lymphoma in Mice
Abstract 159 About one-third of diffuse large B-cell lymphoma (DLBCL) patients develop relapsed/refractory disease, a major cause of morbidity and mortality. Of DLBCL, 5% are double-hit lymphomas (DHLs) with translocations of MYC and BCL2 characterized by poor outcomes with R-CHOP. Auroras (A and B)...
Saved in:
Published in | Blood Vol. 120; no. 21; p. 159 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
16.11.2012
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract 159
About one-third of diffuse large B-cell lymphoma (DLBCL) patients develop relapsed/refractory disease, a major cause of morbidity and mortality. Of DLBCL, 5% are double-hit lymphomas (DHLs) with translocations of MYC and BCL2 characterized by poor outcomes with R-CHOP. Auroras (A and B) are a family of mitotic oncogenic serine/threonine kinases required for high fidelity regulation of the mitotic phase of the cell cycle. Aberrant over-expression of Auroras leads to genetic instability, polyploidy and resistance to microtubule targeted agents. Previously we showed Aurora inhibitor (MLN8237, alisertib) [M] plus vincristine [V] plus rituximab [R] is synthetic lethal and a potential curative therapy in a mantle cell lymphoma model (Granta-519) with several cell cycle genetic defects [t (11;14)], ATM (haploinsufficient), p16/p14 (Del)] but p53 (WT). We evaluated ABC-DLBCL cell lines TMD-8 and U-2932 where the BCR/NF-kB pathway is constitutively active. In TMD-8, CD79B is mutated and in U-2932, Bcl2 [3q27] and Bcl6 [18q21] are amplified, p53 (mutated) and c-Myc over-expressed [DHL]. Triple therapy with MVR abolished proliferation, disrupted cell cycle processes and induced apoptosis compared to single agent and doublet treatments. A Mouse xenograft model of U-2932 showed modest activity for M (30 mg kg, PO, QD, 3 weeks), V (0.375 mg/kg, IV, Q1Wx3) and MV with tumor growth inhibition (TGI) of ∼10% (p=0.01) respectively. However, R (10 mg/kg, IV, Q1Wx3) alone induced ∼ 50% TGI (p=0.01) due to effective targeting of Bcl2. Doublets MR and VR led to tumor regression (TR), but relapse soon after stopping therapy. In contrast, MVR demonstrated TR with no relapses >40 days after stopping therapy. All treatments were well tolerated (no weight loss) and Kaplan-Meier analysis showed that mice treated with MR, VR and MVR had a statistically significant improvement in overall survival compared to control, M, V and MV (p<0.0001). Moreover, with MVR, OS was 100% (Figure 1). Gene expression profiling, RT-PCR, IHC and Western blotting of harvested tumors at the end of treatment (3 weeks) has been interrogated to ascertain the mechanistic role of Aurora inhibition when added to R [R Vs MR] and VR [VR Vs MVR]. Thus, addition of R to MV represents a novel therapeutic strategy that is currently under clinical trial evaluation in aggressive B-NHL including double hit lymphomas sponsored by Millennium Pharmaceuticals (C14011).
[Display omitted]
No relevant conflicts of interest to declare. |
---|---|
AbstractList | Abstract 159
About one-third of diffuse large B-cell lymphoma (DLBCL) patients develop relapsed/refractory disease, a major cause of morbidity and mortality. Of DLBCL, 5% are double-hit lymphomas (DHLs) with translocations of MYC and BCL2 characterized by poor outcomes with R-CHOP. Auroras (A and B) are a family of mitotic oncogenic serine/threonine kinases required for high fidelity regulation of the mitotic phase of the cell cycle. Aberrant over-expression of Auroras leads to genetic instability, polyploidy and resistance to microtubule targeted agents. Previously we showed Aurora inhibitor (MLN8237, alisertib) [M] plus vincristine [V] plus rituximab [R] is synthetic lethal and a potential curative therapy in a mantle cell lymphoma model (Granta-519) with several cell cycle genetic defects [t (11;14)], ATM (haploinsufficient), p16/p14 (Del)] but p53 (WT). We evaluated ABC-DLBCL cell lines TMD-8 and U-2932 where the BCR/NF-kB pathway is constitutively active. In TMD-8, CD79B is mutated and in U-2932, Bcl2 [3q27] and Bcl6 [18q21] are amplified, p53 (mutated) and c-Myc over-expressed [DHL]. Triple therapy with MVR abolished proliferation, disrupted cell cycle processes and induced apoptosis compared to single agent and doublet treatments. A Mouse xenograft model of U-2932 showed modest activity for M (30 mg kg, PO, QD, 3 weeks), V (0.375 mg/kg, IV, Q1Wx3) and MV with tumor growth inhibition (TGI) of ∼10% (p=0.01) respectively. However, R (10 mg/kg, IV, Q1Wx3) alone induced ∼ 50% TGI (p=0.01) due to effective targeting of Bcl2. Doublets MR and VR led to tumor regression (TR), but relapse soon after stopping therapy. In contrast, MVR demonstrated TR with no relapses >40 days after stopping therapy. All treatments were well tolerated (no weight loss) and Kaplan-Meier analysis showed that mice treated with MR, VR and MVR had a statistically significant improvement in overall survival compared to control, M, V and MV (p<0.0001). Moreover, with MVR, OS was 100% (Figure 1). Gene expression profiling, RT-PCR, IHC and Western blotting of harvested tumors at the end of treatment (3 weeks) has been interrogated to ascertain the mechanistic role of Aurora inhibition when added to R [R Vs MR] and VR [VR Vs MVR]. Thus, addition of R to MV represents a novel therapeutic strategy that is currently under clinical trial evaluation in aggressive B-NHL including double hit lymphomas sponsored by Millennium Pharmaceuticals (C14011).
[Display omitted]
No relevant conflicts of interest to declare. Abstract 159 About one-third of diffuse large B-cell lymphoma (DLBCL) patients develop relapsed/refractory disease, a major cause of morbidity and mortality. Of DLBCL, 5% are double-hit lymphomas (DHLs) with translocations of MYC and BCL2 characterized by poor outcomes with R-CHOP. Auroras (A and B) are a family of mitotic oncogenic serine/threonine kinases required for high fidelity regulation of the mitotic phase of the cell cycle. Aberrant over-expression of Auroras leads to genetic instability, polyploidy and resistance to microtubule targeted agents. Previously we showed Aurora inhibitor (MLN8237, alisertib) [M] plus vincristine [V] plus rituximab [R] is synthetic lethal and a potential curative therapy in a mantle cell lymphoma model (Granta-519) with several cell cycle genetic defects [t (11;14)], ATM (haploinsufficient), p16/p14 (Del)] but p53 (WT). We evaluated ABC-DLBCL cell lines TMD-8 and U-2932 where the BCR/NF-kB pathway is constitutively active. In TMD-8, CD79B is mutated and in U-2932, Bcl2 [3q27] and Bcl6 [18q21] are amplified, p53 (mutated) and c-Myc over-expressed [DHL]. Triple therapy with MVR abolished proliferation, disrupted cell cycle processes and induced apoptosis compared to single agent and doublet treatments. A Mouse xenograft model of U-2932 showed modest activity for M (30 mg kg, PO, QD, 3 weeks), V (0.375 mg/kg, IV, Q1Wx3) and MV with tumor growth inhibition (TGI) of ∼10% (p=0.01) respectively. However, R (10 mg/kg, IV, Q1Wx3) alone induced ∼ 50% TGI (p=0.01) due to effective targeting of Bcl2. Doublets MR and VR led to tumor regression (TR), but relapse soon after stopping therapy. In contrast, MVR demonstrated TR with no relapses >40 days after stopping therapy. All treatments were well tolerated (no weight loss) and Kaplan-Meier analysis showed that mice treated with MR, VR and MVR had a statistically significant improvement in overall survival compared to control, M, V and MV (p<0.0001). Moreover, with MVR, OS was 100% (Figure 1). Gene expression profiling, RT-PCR, IHC and Western blotting of harvested tumors at the end of treatment (3 weeks) has been interrogated to ascertain the mechanistic role of Aurora inhibition when added to R [R Vs MR] and VR [VR Vs MVR]. Thus, addition of R to MV represents a novel therapeutic strategy that is currently under clinical trial evaluation in aggressive B-NHL including double hit lymphomas sponsored by Millennium Pharmaceuticals (C14011). Figure 1: Kaplan-Meier Survival by Treatment: MLN8237 (M), Rituximab (R), Vincristine (V), MR, MV, VR, MVR in a U-2932 ABC-DLBCL SCID Mouse Xenograft Model Figure 1:. Kaplan-Meier Survival by Treatment: MLN8237 (M), Rituximab (R), Vincristine (V), MR, MV, VR, MVR in a U-2932 ABC-DLBCL SCID Mouse Xenograft Model Disclosures: No relevant conflicts of interest to declare. |
Author | Mahadevan, Daruka |
Author_xml | – sequence: 1 givenname: Daruka surname: Mahadevan fullname: Mahadevan, Daruka organization: Research, The West Clinic, Memphis, TN, USA |
BookMark | eNqFkMlOAzEQRC0EEmH5BKT-gQm2M-sJhbBKg5BYcrU8dps0moyR7SBy5M9JAncOpb5UlbreEdsf_ICMnQk-FqKW513vvR3PheRjKcaiaLbaYyNRyDrjXPJ9NuKcl1neVOKQHcX4zrnIJ7IYse9pTxFDog6m1qKF5OGJ0uqLlroDPViY02ACxUQDwn2E5_WQFpjIQItpofudZ7YKOtEngndw5Vddj3BHCa7IuVVEaHV4Q7jMZtj30K6XHwu_1EADPJDBE3bgdB_x9O8es9eb65fZXdY-3t7Ppm1mBJdNlsvGFR13fOKckU7WVVGiEbbOq7ypLQojjc4rbUuUlXUlltVENnnV2MJy2_DJMSt-e03wMQZ06iNsRoa1ElxtOaodR7XlqKRQG4ZbbXIXvzncPPdJGFQ0hINBSwFNUtbTPw0_nuZ_gw |
ContentType | Journal Article |
Copyright | 2012 American Society of Hematology |
Copyright_xml | – notice: 2012 American Society of Hematology |
DBID | 6I. AAFTH AAYXX CITATION |
DOI | 10.1182/blood.V120.21.159.159 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology Anatomy & Physiology |
EISSN | 1528-0020 |
EndPage | 159 |
ExternalDocumentID | 10_1182_blood_V120_21_159_159 S0006497118528500 |
GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6I. 6J9 AAEDW AAFTH AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 0R~ 0SF AALRI AAYXX ADVLN AITUG AKRWK AMRAJ CITATION H13 |
ID | FETCH-LOGICAL-c1029-429f5b0f03ffc2f28756ec1d847498de1c2ca47ad6e27df6e67329479d5d0d903 |
IEDL.DBID | ABVKL |
ISSN | 0006-4971 |
IngestDate | Fri Aug 23 00:35:31 EDT 2024 Fri Feb 23 02:43:00 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 21 |
Language | English |
License | This article is made available under the Elsevier license. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1029-429f5b0f03ffc2f28756ec1d847498de1c2ca47ad6e27df6e67329479d5d0d903 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0006497118528500 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1182_blood_V120_21_159_159 elsevier_sciencedirect_doi_10_1182_blood_V120_21_159_159 |
PublicationCentury | 2000 |
PublicationDate | 2012-11-16 |
PublicationDateYYYYMMDD | 2012-11-16 |
PublicationDate_xml | – month: 11 year: 2012 text: 2012-11-16 day: 16 |
PublicationDecade | 2010 |
PublicationTitle | Blood |
PublicationYear | 2012 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
SSID | ssj0014325 |
Score | 2.104928 |
Snippet | Abstract 159
About one-third of diffuse large B-cell lymphoma (DLBCL) patients develop relapsed/refractory disease, a major cause of morbidity and mortality.... |
SourceID | crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | 159 |
Title | Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Curative of Double Hit Diffuse Large B-Cell Lymphoma in Mice |
URI | https://dx.doi.org/10.1182/blood.V120.21.159.159 |
Volume | 120 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB6VVDwuCFIQ5VHNAXFzYm_82D06hirQBIlHo94s70tdKXEq6kjkyD9n1g8EEuLAwZJlee3Vzni-bzwzOwCvleKCqyQMsjRNglgpG0jFVcCkjLlgJpbGR3RXH9PFZfzhKrk6gmKohfFplb3t72x6a637K9N-Nac3zvkaX4JTkUW-_JcnIfntx8yHmUZwnM_XF8tfwYR4xrpGBuQ8-wF9IQ8x62mbHT5ZRyycsGhC0O6Pv0PUb7Bz_gge9nwR825Kj-HI1GM4yWvylbcHfINtBmf7a3wMd-fD2f1i6OM2hnurPnx-Aj_yjW-93DiJORkcjc0OP7tm_91tK4lVrXHtatV-9rXB97f45VATQaRX49I01zQPf0-x73YLx51F4t9yY3DhGnzrrN3fGlz63HKcB4XZbHB5IG3ZbSt0Na7IJj2By_N3X4tF0PdgCFTkM2MIrmwiQxvOrFXMkn-VpEZFmkAtFlybSDFVxVmlU8MybVOTZjMm4kzoRIdahLOnMKp3tXkGmFprmRWVFVbFitEjmFCkQ5WwEdFAcQqTYdnLm26rjbJ1UTgrWzmVXk4li0qSkT9OgQ_CKf_QmZLg4N9Dn___0BfwgEgT8_WIUfoSRs23vXlFxKSRZ73incGdi0_8J0Ma4WU |
link.rule.ids | 315,786,790,27600,27955,27956,45696 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqVlAuqGxBlEeZA-KW3cTrPHzMhlZbmu0B2lVvVuzYqqVdb0WzEnvknzPOA4GEeuBgKYrixPJM5vvGnvEQ8lGpjGcqDoM0SeKAKWUCqTIVUClZxqlmUvsd3cVVMr9hX27j2z1SDLkwPqyyt_2dTW-tdX9n0s_m5N5an-OLcMrTyKf_ZnGIfvsBsgGOan6Qz5aX5e_NBDalXSEDdJ59hz6RB5n1pI0OHy8jGo5pNEZo9-3fEPUH7Jwfkec9X4S8G9ILsqfdiBznDn3l9Q4-QRvB2S6Nj8iT2XB1WAx13Ebk6aLfPj8mP_OVL73cWAk5Gpwamg18tc32h11XEipXw9I61f72TsPFA3zbOSSI-GkodXOH4_DPFNvutHDYGED-LVca5raBz9aY7YOG0seWwywo9GoF5Q61ZbOuwDpYoE16SW7Oz66LedDXYAhU5CNjEK5MLEMTTo1R1KB_FSdaRTWCGuNZrSNFVcXSqk40TWuT6CSdUs5SXsd1WPNw-orsu43TrwkkxhhqeGW4UUxRfAXlCnWo4iZCGshPyHiYdnHfHbUhWhclo6KVk_ByEjQSKCPfTkg2CEf8pTMC4eDxrm_-v-sHcji_XpSivLi6fEueIYGiPjcxSt6R_eb7Vr9HktLI014JfwHJneNp |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Alisertib+Added+to+Rituximab+and+Vincristine+Is+Synthetic+Lethal+and+Curative+of+Double+Hit+Diffuse+Large+B-Cell+Lymphoma+in+Mice&rft.jtitle=Blood&rft.au=Mahadevan%2C+Daruka&rft.date=2012-11-16&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=120&rft.issue=21&rft.spage=159&rft.epage=159&rft_id=info:doi/10.1182%2Fblood.V120.21.159.159&rft.externalDBID=n%2Fa&rft.externalDocID=10_1182_blood_V120_21_159_159 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |